Abstract: The present invention provides antibodies and antigen-binding fragments (e.g., human antibodies) that bind specifically to human IL2 receptor gamma (IL2R?). Methods for treating or preventing diseases mediated by IL2R? (e.g., graft vs host disease) using the antibodies and fragments are also provided along with methods of making the antibodies and fragments.
Abstract: A prefilled syringe and a method of filling a syringe with a pegfilgrastim solution to provide a target extracted volume of pegfilgrastim solution from the syringe are described. A method includes selecting the target extracted volume of pegfilgrastim solution, determining an estimated drug transfer loss, determining an estimated syringe dead volume, filling the syringe with a volume of pegfilgrastim solution comprising at least the target extracted volume plus the estimated drug transfer loss plus the estimated syringe dead volume.
Type:
Grant
Filed:
March 11, 2021
Date of Patent:
March 14, 2023
Assignee:
FRESENIUS KABI DEUTSCHLAND GMBH
Inventors:
Florence Roger, Fabien Vaudant, Thierry Rimlinger, Christian Ebert, Rodrigue Chatton, Alexander Degen, Kevin Reitz, Torsten Brandenburger
Abstract: The present invention aims to provide a method for simply and highly accurately detecting castration-resistant prostate cancer (CRPC), and a reagent that can be used for this method. By measuring the level of GDF15 propeptide present in a sample as a novel detection marker for CRPC, acquisition of castration resistance in a prostate cancer patient during or after endocrine therapy is detected. An antibody that specifically recognizes GDF15 propeptide is included in the CRPC detection reagent.
Type:
Grant
Filed:
February 23, 2017
Date of Patent:
March 14, 2023
Assignees:
PUBLIC UNIVERSITY CORPORATION YOKOHAMA CITY UNIVERSITY, TOSOH CORPORATION
Abstract: Administration regimens for therapeutic proteins (e.g., T cell-activating bispecific antibodies) that mitigate cytokine release syndrome and infusion-related reaction are disclosed. The methods employ initial fractional dosing with optional administration of additional agents such as steroids or cytokine antagonists that are discontinued with maximal weekly dosing over the course of the dosing regimen.
Type:
Grant
Filed:
August 30, 2019
Date of Patent:
February 28, 2023
Assignee:
Regeneron Pharmaceuticals, Inc.
Inventors:
Carrie Brownstein, Israel Lowy, Lieve Lucille Adriaens
Abstract: The present invention relates to a bispecific antibody construct comprising a first binding domain which binds to human DLL3 on the surface of a target cell and a second binding domain which binds to human CD3 on the surface of a T cell. Moreover, the invention provides a polynucleotide encoding the antibody construct, a vector comprising the polynucleotide and a host cell transformed or transfected with the polynucleotide or vector. Furthermore, the invention provides a process for the production of the antibody construct of the invention, a medical use of the antibody construct and a kit comprising the antibody construct.
Type:
Grant
Filed:
May 6, 2020
Date of Patent:
February 28, 2023
Assignee:
AMGEN RESEARCH (MUNICH) GMBH
Inventors:
Tobias Raum, Claudia Blümel, Christoph Dahlhoff, Patrick Hoffmann, Peter Kufer, Ralf Lutterbüse, Elisabeth Nahrwold, Jochen Pendzialek
Abstract: Provided herein are protein-based purification matrices and methods of use thereof to purify biologics and/or to remove contaminants from a composition. Methods of bringing two or more biologics in close proximity are also provided. The disclosed compositions and methods allow for faster, more efficient purification of a biologic compared to traditional affinity chromatography.
Abstract: Disclosed are compositions and methods for treating disease or condition caused or exacerbated by S100A9 activity, such as myelodysplastic syndromes (MDS) using a composition comprising an effective amount of a CD33/S100A9 inhibitor.
Type:
Grant
Filed:
June 25, 2019
Date of Patent:
February 21, 2023
Assignee:
H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC.
Abstract: The present invention is directed to novel bispecific heterodimeric Fc fusion proteins comprising an IL-15/IL-15R? Fc-fusion protein and a PD-1 antibody fragment-Fc fusion protein.
Type:
Grant
Filed:
December 17, 2019
Date of Patent:
February 21, 2023
Assignee:
Xencor, Inc.
Inventors:
Matthew Bernett, Rumana Rashid, John Desjarlais, Rajat Varma, Christine Bonzon
Abstract: Described herein are methods of treating COVID19 from a coronavirus infection, methods of treating a subject having a coronavirus infection, methods of improving a survival rate of a subject having a coronavirus infection, methods of determining prognosis of a subject having a coronavirus infection, methods of preventing or treating organ-dysfunction or multi-organ dysfunction or failure associated with a coronavirus infection, methods of combinational therapy for a subject having a coronavirus infection, methods of reducing microthrombi formation or low flow organ-ischemia associated with a coronavirus infection by administering a DEspR inhibitor.
Abstract: The present invention relates to antigen-binding compounds that inhibit the enzymatic activity of soluble human CD39. The invention also relates to cells producing such compounds; methods of making such compounds, and antibodies, fragments, variants, and derivatives thereof; pharmaceutical compositions comprising the same; methods of using the compounds to diagnose, treat or prevent diseases, e.g., cancer.
Type:
Grant
Filed:
March 16, 2018
Date of Patent:
February 14, 2023
Assignees:
INNATE PHARMA, OREGA BIOTECH
Inventors:
Stéphanie Chanteux, Nicolas Gourdin, Carine Paturel, Ivan Perrot, Benjamin Rossi
Abstract: A method of treating psoriasis in a patient by administering an IL-23 specific antibody, e.g., guselkumab, in a clinically proven safe and clinically proven effective amount and the patient achieves PASI90, PASI100 or IGA 0 or 1 score as measured 16, 24, 32, 40 and 48 weeks after initial treatment and the patient achieves higher efficacy than a patient treated with the secukinumab antibody.
Type:
Grant
Filed:
November 19, 2019
Date of Patent:
January 10, 2023
Assignee:
JANSSEN BIOTECH, INC.
Inventors:
Julianty Angsana, Patrick Branigan, Samuel DePrimo, Susan Flavin, Shu Li, Xuejun Liu, Ernesto Munoz, Bruce Randazzo
Abstract: Human interleukin-2 (IL-2) muteins or variants thereof are provided. In particular, provided are IL-2 muteins that have an increased binding capacity for IL-2R? receptor as compared to wild-type IL-2 for use in combination therapies with anti-PD-1 antibodies for the treatment of cancer. Also provided are pharmaceutical compositions that include such anti-PD-1 antibodies and the disclosed IL-2 muteins.
Abstract: The present invention provides antibodies and antigen-binding fragments of antibodies that bind to leptin receptor (LEPR), and methods of using the same. According to certain embodiments, the invention includes antibodies and antigen-binding fragments of antibodies that bind LEPR and antagonize LEPR signaling. In certain embodiments, the invention includes antibodies and antigen-binding fragments of antibodies that bind LEPR in the presence or absence of leptin. In other embodiments, the invention includes antibodies and antigen-binding fragments of antibodies that exhibit partial agonism of LEPR signaling.
Abstract: Provided is an antibody that specifically recognizes IL-13RA2, which can be used in the manufacture of a targeting anti-tumor medicament as well as a medicament for diagnosing a tumor.
Abstract: Provided are methods and compositions to target delivery of cells to a tissue lesion, thereby treating the lesion. For example, biotinylated antibodies with affinity to a lesion epitope are administered at the lesion. Reparative cells including avidin and biotin are then administered at the lesion. The reparative cells are targeted to the lesion via avidin-biotin bridges to the antibodies, with additional cells recruited to the lesion via cell-to-cell avidin-biotin bridges. In certain examples, antibody-reparative cell complexes are formed by mixing the biotinylated antibodies with the reparative cells including avidin and biotin. The complexes are then administered at the lesion. In other examples, multivalent antibodies are used to target reparative cells to the lesion, such as by binding an epitope at the lesion and an epitope present on the reparative cell. In other examples, the antibodies are chemically linked to a reparative cell or to a nanosome containing a therapeutic agent.
Type:
Grant
Filed:
November 18, 2019
Date of Patent:
December 20, 2022
Inventors:
Karen Hasty, John Stuart, Mary Christine Patterson, Hongsik Cho
Abstract: The present invention is directed to novel PD-1-targeted IL-15/R?-Fc fusion proteins comprising an IL-15/IL-15R? Fc-fusion protein and a PD-1 antigen binding domain. The PD-1-targeted IL-15/R?-Fc fusion proteins can be administered to a patient to treat cancer.
Type:
Grant
Filed:
April 18, 2019
Date of Patent:
December 13, 2022
Assignee:
Xencor, Inc.
Inventors:
Matthew Bernett, John Desjarlais, Rumana Rashid, Rajat Varma, Christine Bonzon
Abstract: The present invention is situated in the field of multimers used for targeted therapies. More particularly, the invention relates to methods for preparing multifunctional heteromultimeric protein complexes with a defined ratio of functional components and to multifunctional heteromultimeric protein complexes for directing complement-dependent cytolysis, optionally comprising a scaffold, which display three or more different functional components present in a defined relative ratio, of which one is a tracking component.
Type:
Grant
Filed:
May 22, 2017
Date of Patent:
December 6, 2022
Assignees:
Luxembourg Institute of Health (LIH), Université de Reims Champagne Ardenne URCA
Inventors:
Xavier Dervillez, Carole Devaux, Jacques H. M. Cohen
Abstract: The present invention is directed to novel targeted heterodimeric fusion proteins comprising an IL-15/IL-15R? Fc-fusion protein and a TIM-3 antibody fragment-Fc fusion protein.
Type:
Grant
Filed:
April 18, 2019
Date of Patent:
November 22, 2022
Assignee:
Xencor, Inc.
Inventors:
Matthew J. Bernett, John Desjarlais, Rumana Rashid, Rajat Varma, Christine Bonzon
Abstract: The present invention, in the field of bioengineering and biotechnology, relates to a method for preparing a recombinant antibody with a unique glycan profile produced by a genome-edited CHO host cell. Specifically, according to a method of the present invention, the TALEN technology is used to edit the FUT8 gene in CHO cells that have been adapted for serum-free suspension growth. The edited CHO host cells can produce recombinant antibodies with a unique glycan profile. The unique glycan profile can be characterized by non-fucosylated N-linked oligosaccharide chains of the antibodies, extremely low N-glycosylation heterogeneity and uniform carbohydrate chains. The antibody prepared by the method of the invention exhibit significantly increased ADCC and greater stability.